CN109563158B - 抗补体因子bb抗体以及其用途 - Google Patents

抗补体因子bb抗体以及其用途 Download PDF

Info

Publication number
CN109563158B
CN109563158B CN201780029742.9A CN201780029742A CN109563158B CN 109563158 B CN109563158 B CN 109563158B CN 201780029742 A CN201780029742 A CN 201780029742A CN 109563158 B CN109563158 B CN 109563158B
Authority
CN
China
Prior art keywords
antibody
amino acid
seq
acid sequence
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780029742.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN109563158A (zh
Inventor
桑迪普·帕尼克
格雷汉姆·帕里
凯伦·苏·克里斯托弗森
托尼·桑永·布云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Biobelli America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biobelli America filed Critical Biobelli America
Priority to CN202210862505.3A priority Critical patent/CN116790614A/zh
Publication of CN109563158A publication Critical patent/CN109563158A/zh
Application granted granted Critical
Publication of CN109563158B publication Critical patent/CN109563158B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780029742.9A 2016-04-04 2017-04-03 抗补体因子bb抗体以及其用途 Active CN109563158B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210862505.3A CN116790614A (zh) 2016-04-04 2017-04-03 抗补体因子bb抗体以及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317897P 2016-04-04 2016-04-04
US62/317,897 2016-04-04
PCT/US2017/025784 WO2017176651A1 (en) 2016-04-04 2017-04-03 Anti-complement factor bb antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210862505.3A Division CN116790614A (zh) 2016-04-04 2017-04-03 抗补体因子bb抗体以及其用途

Publications (2)

Publication Number Publication Date
CN109563158A CN109563158A (zh) 2019-04-02
CN109563158B true CN109563158B (zh) 2022-08-09

Family

ID=60000646

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780029742.9A Active CN109563158B (zh) 2016-04-04 2017-04-03 抗补体因子bb抗体以及其用途
CN202210862505.3A Pending CN116790614A (zh) 2016-04-04 2017-04-03 抗补体因子bb抗体以及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210862505.3A Pending CN116790614A (zh) 2016-04-04 2017-04-03 抗补体因子bb抗体以及其用途

Country Status (23)

Country Link
US (3) US10934347B2 (enExample)
EP (1) EP3452510A4 (enExample)
JP (3) JP6967528B2 (enExample)
KR (2) KR20240096672A (enExample)
CN (2) CN109563158B (enExample)
AU (2) AU2017246794B2 (enExample)
BR (1) BR112018070357A2 (enExample)
CA (1) CA3019332A1 (enExample)
CL (1) CL2018002810A1 (enExample)
CO (1) CO2018010827A2 (enExample)
CR (1) CR20180529A (enExample)
DO (1) DOP2018000219A (enExample)
EA (1) EA201892225A1 (enExample)
EC (1) ECSP18082302A (enExample)
IL (3) IL311675A (enExample)
MA (1) MA44878A (enExample)
MX (2) MX2018012176A (enExample)
MY (1) MY194603A (enExample)
PE (1) PE20190209A1 (enExample)
PH (1) PH12018502137A1 (enExample)
SG (1) SG11201808525UA (enExample)
TN (1) TN2018000341A1 (enExample)
WO (1) WO2017176651A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2598533B1 (en) 2010-07-28 2019-02-20 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
AU2016297862C1 (en) 2015-07-24 2022-12-15 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding
TN2018000341A1 (en) 2016-04-04 2020-06-15 Bioverativ Usa Inc ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF.
PE20191354A1 (es) 2016-12-09 2019-10-01 Gliknik Inc Optimizacion de fabricacion de gl-2045, un stradomer multimerizante
KR20190093186A (ko) * 2016-12-09 2019-08-08 글리크닉 인코포레이티드 다가 Fc 화합물에 의해 염증성 장애를 치료하는 방법
EP3570894A4 (en) * 2017-01-17 2021-04-07 The Texas A&M University System ENDOLYSOSOMAL TARGETING CONJUGATES FOR BETTER LOAD MOLECULES DISTRIBUTION TO ENDOLYSOSOMAL COMPARTMENT OF TARGET CELLS
EP3694874A1 (en) 2017-10-11 2020-08-19 Bioverativ USA Inc. Methods of inducing complement activity
JP7403165B2 (ja) 2017-12-19 2023-12-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 血液脳関門を通過してウイルスベクターを送達するための方法および組成物
CA3142840A1 (en) * 2019-06-27 2020-12-30 Verseau Therapeutics, Inc. Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
CA3147638A1 (en) * 2019-07-17 2021-01-21 Gemini Therapeutics Sub, Inc. Factor h potentiating antibodies and uses thereof
WO2021167949A1 (en) * 2020-02-18 2021-08-26 Children's Hospital Medical Center Compositions and methods for treating liver disease
KR20230004686A (ko) 2020-04-20 2023-01-06 젠자임 코포레이션 인간화 항-보체 인자 Bb 항체 및 그의 용도
JP7787164B2 (ja) 2020-09-23 2025-12-16 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体媒介性障害の治療のための医薬化合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918444A (zh) * 2007-11-08 2010-12-15 健泰科生物技术公司 抗因子b抗体及其用途
CN104220454A (zh) * 2012-04-03 2014-12-17 诺沃姆德治疗公司 人源化的嵌合抗因子Bb抗体及其用途
CN104884088A (zh) * 2012-11-02 2015-09-02 真北医疗股份有限公司 抗补体C1s抗体和其用途
JP2020078304A (ja) * 2014-02-27 2020-05-28 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体因子Ｂｂ抗体

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
KR20060099543A (ko) 1994-12-09 2006-09-19 임페리얼 컬리지 이노베이션스 리미티드 유전자의 동정
AU4188196A (en) 1994-12-22 1996-07-10 Nissan Chemical Industries Ltd. Organobismuth derivatives and process for producing the same
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
PT939647E (pt) 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
ZA9811379B (en) 1997-12-12 1999-08-27 Macromed Inc Hetero-functionalized star-shaped poly(ethylene glycols) for protein modification.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
PL1713503T3 (pl) 2004-02-10 2014-02-28 Univ Colorado Regents Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
SI2500030T2 (sl) 2005-11-04 2018-11-30 Genentech, Inc. Uporaba inhibitorjev komplementarnih procesov za zdravljenje očesnih bolezni
PT2532681E (pt) * 2005-12-20 2014-12-23 Sbi Biotech Co Ltd Anticorpos anti-ilt7
WO2009029669A1 (en) 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CA2745499A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Peptide therapeutic conjugates and uses thereof
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
EP2755688A4 (en) 2011-10-27 2014-08-06 Nkt Therapeutics Inc HUMANIZED ANTIBODIES AGAINST INKT
ES2812849T3 (es) * 2012-02-24 2021-03-18 Abbvie Stemcentrx Llc Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
WO2014044793A2 (en) 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US10035847B2 (en) * 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
BR112018000768A2 (pt) 2015-07-13 2018-09-25 Cytomx Therapeutics Inc anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
TN2018000341A1 (en) 2016-04-04 2020-06-15 Bioverativ Usa Inc ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF.
EP3694874A1 (en) 2017-10-11 2020-08-19 Bioverativ USA Inc. Methods of inducing complement activity
KR20230004686A (ko) 2020-04-20 2023-01-06 젠자임 코포레이션 인간화 항-보체 인자 Bb 항체 및 그의 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918444A (zh) * 2007-11-08 2010-12-15 健泰科生物技术公司 抗因子b抗体及其用途
CN104220454A (zh) * 2012-04-03 2014-12-17 诺沃姆德治疗公司 人源化的嵌合抗因子Bb抗体及其用途
CN104884088A (zh) * 2012-11-02 2015-09-02 真北医疗股份有限公司 抗补体C1s抗体和其用途
JP2020078304A (ja) * 2014-02-27 2020-05-28 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体因子Ｂｂ抗体

Also Published As

Publication number Publication date
CO2018010827A2 (es) 2018-11-22
PE20190209A1 (es) 2019-02-07
PH12018502137A1 (en) 2019-09-23
CA3019332A1 (en) 2017-10-12
JP2023139289A (ja) 2023-10-03
KR20240096672A (ko) 2024-06-26
EP3452510A4 (en) 2020-01-15
JP2021191789A (ja) 2021-12-16
US20240228599A1 (en) 2024-07-11
EA201892225A1 (ru) 2019-09-30
ECSP18082302A (es) 2019-01-31
WO2017176651A1 (en) 2017-10-12
SG11201808525UA (en) 2018-10-30
IL295288B2 (en) 2024-08-01
CL2018002810A1 (es) 2019-03-15
KR102673420B1 (ko) 2024-06-07
US11851482B2 (en) 2023-12-26
TN2018000341A1 (en) 2020-06-15
IL262010A (en) 2018-10-31
US20210221877A1 (en) 2021-07-22
NZ747018A (en) 2025-05-02
AU2024224000A1 (en) 2024-12-19
MX2023007149A (es) 2023-06-28
KR20190003951A (ko) 2019-01-10
CN109563158A (zh) 2019-04-02
EP3452510A1 (en) 2019-03-13
BR112018070357A2 (pt) 2019-01-29
JP2019513726A (ja) 2019-05-30
US10934347B2 (en) 2021-03-02
MA44878A (fr) 2019-03-13
AU2017246794B2 (en) 2024-07-04
AU2017246794A1 (en) 2018-10-25
CN116790614A (zh) 2023-09-22
MX2018012176A (es) 2019-02-07
DOP2018000219A (es) 2019-03-31
US20190153079A1 (en) 2019-05-23
MY194603A (en) 2022-12-06
IL311675A (en) 2024-05-01
JP6967528B2 (ja) 2021-11-17
IL295288B1 (en) 2024-04-01
JP7326393B2 (ja) 2023-08-15
CR20180529A (es) 2019-03-21
IL295288A (en) 2022-10-01
IL262010B (en) 2022-09-01

Similar Documents

Publication Publication Date Title
US20240228599A1 (en) Anti-complement factor bb antibodies and uses thereof
US12240917B2 (en) Anti-complement C1s antibodies and uses thereof
JP2022537672A (ja) 抗ｂ７－ｈ３抗体およびその使用方法
HK40006720A (en) Anti-complement factor bb antibodies and uses thereof
HK40063408A (en) Anti-complement c1s antibodies and uses thereof
NZ786930A (en) Anti-complement factor Bb antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40006720

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240410

Address after: Massachusetts, USA

Patentee after: Genzyme Corp.

Country or region after: U.S.A.

Address before: California, USA

Patentee before: Biobelli America

Country or region before: U.S.A.

TR01 Transfer of patent right